Combining Geometry, Topology and Semantics for Generic Building Description and Simulations

International audience2D and 3D virtual architectural models are the common ground of many studies, including environmental protection , energy saving, or human well-being. Building or urban environment simulations concern for instance heat transfer, lighting, and acoustics, each of them requiring physical parameters additionally to the geometric representation. Furthermore, geometry does not generally comply straightforwardly with physical parameters and users are forced to manually adapt the models before simulation. This paper proposes an overview of modeling and simulation studies that make use of topological representations, and discusses the advantages of a topological representation for various types of applications. Such a representation can be used not only to maintain the 3D model global coherence, but also to automatically retrieve walls, doors, or room volumes for instance. Based on the existing model of generalized maps, this paper also illustrates some examples of structure traversal that can be used for providing the users with adequate simulation data

Topological Reconstruction of Complex 3D Buildings and Automatic Extraction of Levels of Detail

International audienceThis paper describes a new method allowing to retrieve the indoor and outdoor topology of a detailed 3D building model from its geometry and to extract different levels of detail (LoD) from the resulting topological description. No prior information about the initial model, except its geometric information is needed as input, and using the combinatorial maps data structure, the method recovers the topological information of the identified parts of the building. The topology is needed for most of the applications using 3D building models after the architects design it. While classical models available are mainly furnished in a Boundary Representation (B-Rep) format, we discuss how to recover the components that allow to distinguish the several parts of the building (defined as volumes) then the spatial relationships linking them

Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study.

HIV-2 is endemic in West Africa. There is a lack of evidence-based guidelines on the diagnosis, management and antiretroviral therapy (ART) for HIV-2 or HIV-1/HIV-2 dual infections. Because of these issues, we designed a West African collaborative cohort for HIV-2 infection within the framework of the International epidemiological Databases to Evaluate AIDS (IeDEA).We collected data on all HIV-2 and HIV-1/HIV-2 dually seropositive patients (both ARV-naive and starting ART) and followed-up in clinical centres in the IeDEA-WA network including a total of 13 clinics in five countries: Benin, Burkina-Faso Côte d'Ivoire, Mali, and Senegal, in the West Africa region.Data was merged for 1,754 patients (56% female), including 1,021 HIV-2 infected patients (551 on ART) and 733 dually seropositive for both HIV-1 and HIV 2 (463 on ART). At ART initiation, the median age of HIV-2 patients was 45.3 years, IQR: (38.3-51.7) and 42.4 years, IQR (37.0-47.3) for dually seropositive patients (p = 0.048). Overall, 16.7% of HIV-2 patients on ART had an advanced clinical stage (WHO IV or CDC-C). The median CD4 count at the ART initiation is 166 cells/mm(3), IQR (83-247) among HIV-2 infected patients and 146 cells/mm(3), IQR (55-249) among dually seropositive patients. Overall, in ART-treated patients, the CD4 count increased 126 cells/mm(3) after 24 months on ART for HIV-2 patients and 169 cells/mm(3) for dually seropositive patients. Of 551 HIV-2 patients on ART, 5.8% died and 10.2% were lost to follow-up during the median time on ART of 2.4 years, IQR (0.7-4.3).This large multi-country study of HIV-2 and HIV-1/HIV-2 dual infection in West Africa suggests that routine clinical care is less than optimal and that management and treatment of HIV-2 could be further informed by ongoing studies and randomized clinical trials in this population